SI2751094T1 - Nova kristalinična oblika - Google Patents

Nova kristalinična oblika

Info

Publication number: SI2751094T1
Authority: SI; Slovenia
Prior art keywords: crystal form; novel crystal; novel; crystal
Prior art date: 2011-09-01

Application number

SI201231371T

Other languages

English (en)

Inventor

Mei-Yin Lee

Original Assignee

Glaxo Group Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-09-01

Filing date

2012-08-31

Publication date

2018-10-30

2012-08-31 Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited

2018-10-30 Publication of SI2751094T1 publication Critical patent/SI2751094T1/sl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Hematology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Liquid Crystal Substances (AREA)
Crystals, And After-Treatments Of Crystals (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Glass Compositions (AREA)

SI201231371T 2011-09-01 2012-08-31 Nova kristalinična oblika SI2751094T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161530104P	2011-09-01	2011-09-01
EP12756693.3A EP2751094B1 (en)	2011-09-01	2012-08-31	Novel crystal form
PCT/EP2012/067027 WO2013030374A1 (en)	2011-09-01	2012-08-31	Novel crystal form

Publications (1)

Publication Number	Publication Date
SI2751094T1 true SI2751094T1 (sl)	2018-10-30

Family

ID=46829730

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI201231371T SI2751094T1 (sl)	2011-09-01	2012-08-31	Nova kristalinična oblika

Country Status (33)

Country	Link
US (3)	US9227953B2 (sl)
EP (1)	EP2751094B1 (sl)
JP (1)	JP6199291B2 (sl)
KR (2)	KR20140056297A (sl)
CN (1)	CN103906744A (sl)
AU (2)	AU2012300841C1 (sl)
BR (1)	BR112014004251A2 (sl)
CA (1)	CA2847066C (sl)
CL (1)	CL2014000489A1 (sl)
CO (1)	CO6890102A2 (sl)
CR (1)	CR20140098A (sl)
CY (1)	CY1120784T1 (sl)
DK (1)	DK2751094T3 (sl)
DO (1)	DOP2014000042A (sl)
EA (1)	EA027972B1 (sl)
ES (1)	ES2686563T3 (sl)
HK (1)	HK1198534A1 (sl)
HR (1)	HRP20181375T1 (sl)
HU (1)	HUE041578T2 (sl)
IL (1)	IL230977A (sl)
LT (1)	LT2751094T (sl)
MA (1)	MA35362B1 (sl)
MX (1)	MX349243B (sl)
MY (1)	MY172885A (sl)
PE (1)	PE20141411A1 (sl)
PL (1)	PL2751094T3 (sl)
PT (1)	PT2751094T (sl)
RS (1)	RS57644B1 (sl)
SG (1)	SG2014011886A (sl)
SI (1)	SI2751094T1 (sl)
UA (1)	UA114607C2 (sl)
WO (1)	WO2013030374A1 (sl)
ZA (1)	ZA201401176B (sl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY172885A (en)	2011-09-01	2019-12-13	Glaxo Group Ltd	Novel crystal form
EP2764866A1 (en)	2013-02-07	2014-08-13	IP Gesellschaft für Management mbH	Inhibitors of nedd8-activating enzyme

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4826689A (en)	1984-05-21	1989-05-02	University Of Rochester	Method for making uniformly sized particles from water-insoluble organic compounds
FR2634376B1 (fr)	1988-07-21	1992-04-17	Farmalyoc	Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
IT1227626B (it)	1988-11-28	1991-04-23	Vectorpharma Int	Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
IT1243390B (it)	1990-11-22	1994-06-10	Vectorpharma Int	Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5552160A (en)	1991-01-25	1996-09-03	Nanosystems L.L.C.	Surface modified NSAID nanoparticles
US5145684A (en)	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
WO1993025190A1 (en)	1992-06-10	1993-12-23	Eastman Kodak Company	Surface modified nsaid nanoparticles
AU660852B2 (en)	1992-11-25	1995-07-06	Elan Pharma International Limited	Method of grinding pharmaceutical substances
US5298262A (en)	1992-12-04	1994-03-29	Sterling Winthrop Inc.	Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en)	1992-12-04	1994-09-13	Sterling Winthrop Inc.	Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5302401A (en)	1992-12-09	1994-04-12	Sterling Winthrop Inc.	Method to reduce particle size growth during lyophilization
US5340564A (en)	1992-12-10	1994-08-23	Sterling Winthrop Inc.	Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en)	1992-12-11	1994-08-09	Sterling Winthrop Inc.	Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en)	1992-12-15	1995-07-04	Eastman Kodak Company	Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en)	1992-12-16	1994-10-04	Sterling Winthrop Inc.	Use of purified surface modifiers to prevent particle aggregation during sterilization
US5587143A (en)	1994-06-28	1996-12-24	Nanosystems L.L.C.	Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5585108A (en)	1994-12-30	1996-12-17	Nanosystems L.L.C.	Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5560932A (en)	1995-01-10	1996-10-01	Nano Systems L.L.C.	Microprecipitation of nanoparticulate pharmaceutical agents
US5662883A (en)	1995-01-10	1997-09-02	Nanosystems L.L.C.	Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en)	1995-01-10	1997-09-09	Nanosystems L.L.C.	Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5569448A (en)	1995-01-24	1996-10-29	Nano Systems L.L.C.	Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5560931A (en)	1995-02-14	1996-10-01	Nawosystems L.L.C.	Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5571536A (en)	1995-02-06	1996-11-05	Nano Systems L.L.C.	Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en)	1995-02-08	1996-04-02	Eastman Kodak Company	Isolation of ultra small particles
US5518738A (en)	1995-02-09	1996-05-21	Nanosystem L.L.C.	Nanoparticulate nsaid compositions
US5534270A (en)	1995-02-09	1996-07-09	Nanosystems Llc	Method of preparing stable drug nanoparticles
US5622938A (en)	1995-02-09	1997-04-22	Nano Systems L.L.C.	Sugar base surfactant for nanocrystals
US5591456A (en)	1995-02-10	1997-01-07	Nanosystems L.L.C.	Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en)	1995-02-13	1996-11-12	Nano Systems L.L.C.	Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en)	1995-02-14	1996-04-23	Nanosystems Llc	Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en)	1995-02-15	1996-12-03	Nano Systems L.L.C.	Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5565188A (en)	1995-02-24	1996-10-15	Nanosystems L.L.C.	Polyalkylene block copolymers as surface modifiers for nanoparticles
US5747001A (en)	1995-02-24	1998-05-05	Nanosystems, L.L.C.	Aerosols containing beclomethazone nanoparticle dispersions
US5718919A (en)	1995-02-24	1998-02-17	Nanosystems L.L.C.	Nanoparticles containing the R(-)enantiomer of ibuprofen
CH690264A5 (fr)	1995-06-30	2000-06-30	Symphar Sa	Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques.
GB9626616D0 (en)	1996-12-20	1997-02-05	Symphar Sa	Novel compounds
GB9626536D0 (en)	1996-12-20	1997-02-05	Symphar Sa	Novel compounds
GB9626615D0 (en)	1996-12-20	1997-02-05	Symphar Sa	Novel compounds
WO1998035666A1 (en)	1997-02-13	1998-08-20	Nanosystems Llc	Formulations of nanoparticle naproxen tablets
GB0024808D0 (en) *	2000-10-10	2000-11-22	Smithkline Beecham Plc	Novel compounds
EP1735457A4 (en)	2004-04-16	2007-08-29	Glaxo Group Ltd	METHODS FOR DETECTING Lp-PLA2 ACTIVITY AND INHIBITION OF Lp-PLA2 ACTIVITY
WO2008140450A1 (en) *	2007-05-11	2008-11-20	Thomas Jefferson University	Methods of treatment and prevention of metabolic bone diseases and disorders
US20080279846A1 (en)	2007-05-11	2008-11-13	Thomas Jefferson University	Methods of treatment and prevention of neurodegenerative diseases and disorders
US8962633B2 (en)	2007-05-11	2015-02-24	Thomas Jefferson University	Methods of treatment and prevention of metabolic bone diseases and disorders
CA2687079A1 (en)	2007-05-11	2008-11-20	The Trustees Of The University Of Pennsylvania	Methods of treatment of skin ulcers
KR101730290B1 (ko)	2007-05-11	2017-04-25	토마스 제퍼슨 유니버시티	신경변성 질환 및 장애의 치료 및 예방 방법
EP2619203A4 (en)	2010-09-20	2014-04-16	Glaxo Group Ltd	TRICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND APPLICATIONS THEREOF
US8859573B2 (en)	2010-12-06	2014-10-14	Glaxo Group Limited	Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2
EP2649053B1 (en)	2010-12-06	2015-11-04	Glaxo Group Limited	Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp-pla2
US20130267544A1 (en)	2010-12-17	2013-10-10	Peter Adamson	Use of LP-PLA2 Inhibitors in the Treatment and Prevention of Eye Diseases
MY172885A (en) *	2011-09-01	2019-12-13	Glaxo Group Ltd	Novel crystal form
EP2764866A1 (en)	2013-02-07	2014-08-13	IP Gesellschaft für Management mbH	Inhibitors of nedd8-activating enzyme

2012
- 2012-08-31 MY MYPI2014700470A patent/MY172885A/en unknown
- 2012-08-31 ES ES12756693.3T patent/ES2686563T3/es active Active
- 2012-08-31 CN CN201280051671.XA patent/CN103906744A/zh active Pending
- 2012-08-31 LT LTEP12756693.3T patent/LT2751094T/lt unknown
- 2012-08-31 MX MX2014002454A patent/MX349243B/es active IP Right Grant
- 2012-08-31 SI SI201231371T patent/SI2751094T1/sl unknown
- 2012-08-31 DK DK12756693.3T patent/DK2751094T3/en active
- 2012-08-31 EA EA201490536A patent/EA027972B1/ru not_active IP Right Cessation
- 2012-08-31 JP JP2014527685A patent/JP6199291B2/ja not_active Expired - Fee Related
- 2012-08-31 PE PE2014000274A patent/PE20141411A1/es not_active Application Discontinuation
- 2012-08-31 EP EP12756693.3A patent/EP2751094B1/en active Active
- 2012-08-31 CA CA2847066A patent/CA2847066C/en not_active Expired - Fee Related
- 2012-08-31 UA UAA201403151A patent/UA114607C2/uk unknown
- 2012-08-31 BR BR112014004251A patent/BR112014004251A2/pt not_active Application Discontinuation
- 2012-08-31 US US14/241,913 patent/US9227953B2/en not_active Expired - Fee Related
- 2012-08-31 WO PCT/EP2012/067027 patent/WO2013030374A1/en active Application Filing
- 2012-08-31 KR KR1020147005011A patent/KR20140056297A/ko not_active Application Discontinuation
- 2012-08-31 PT PT12756693T patent/PT2751094T/pt unknown
- 2012-08-31 SG SG2014011886A patent/SG2014011886A/en unknown
- 2012-08-31 RS RS20181064A patent/RS57644B1/sr unknown
- 2012-08-31 HU HUE12756693A patent/HUE041578T2/hu unknown
- 2012-08-31 AU AU2012300841A patent/AU2012300841C1/en not_active Ceased
- 2012-08-31 KR KR1020197017797A patent/KR20190075172A/ko not_active Application Discontinuation
- 2012-08-31 PL PL12756693T patent/PL2751094T3/pl unknown
2014
- 2014-02-13 IL IL230977A patent/IL230977A/en active IP Right Grant
- 2014-02-17 ZA ZA2014/01176A patent/ZA201401176B/en unknown
- 2014-02-27 CR CR20140098A patent/CR20140098A/es unknown
- 2014-02-27 CL CL2014000489A patent/CL2014000489A1/es unknown
- 2014-02-28 DO DO2014000042A patent/DOP2014000042A/es unknown
- 2014-02-28 MA MA36784A patent/MA35362B1/fr unknown
- 2014-02-28 CO CO14043369A patent/CO6890102A2/es not_active Application Discontinuation
- 2014-11-27 HK HK14111997.4A patent/HK1198534A1/xx not_active IP Right Cessation
2015
- 2015-11-25 US US14/951,997 patent/US9682074B2/en not_active Expired - Fee Related
2016
- 2016-01-28 AU AU2016200492A patent/AU2016200492B2/en not_active Ceased
- 2016-09-01 US US15/254,160 patent/US9694004B2/en not_active Expired - Fee Related
2018
- 2018-08-28 HR HRP20181375TT patent/HRP20181375T1/hr unknown
- 2018-09-04 CY CY181100922T patent/CY1120784T1/el unknown

Also Published As

Publication number	Publication date
MX2014002454A (es)	2014-04-10
CN103906744A (zh)	2014-07-02
EA027972B1 (ru)	2017-09-29
IL230977A0 (en)	2014-03-31
WO2013030374A1 (en)	2013-03-07
RS57644B1 (sr)	2018-11-30
DOP2014000042A (es)	2014-08-31
EP2751094A1 (en)	2014-07-09
AU2016200492A1 (en)	2016-02-18
HRP20181375T1 (hr)	2018-10-19
JP6199291B2 (ja)	2017-09-20
HUE041578T2 (hu)	2019-05-28
EA201490536A1 (ru)	2014-08-29
US9682074B2 (en)	2017-06-20
MX349243B (es)	2017-07-18
ZA201401176B (en)	2015-12-23
JP2014525428A (ja)	2014-09-29
AU2012300841A1 (en)	2014-03-13
CL2014000489A1 (es)	2014-08-01
CA2847066A1 (en)	2013-03-07
BR112014004251A2 (pt)	2017-03-21
CO6890102A2 (es)	2014-03-10
US9227953B2 (en)	2016-01-05
DK2751094T3 (en)	2018-08-20
IL230977A (en)	2016-08-31
MA35362B1 (fr)	2014-08-01
NZ621315A (en)	2016-06-24
SG2014011886A (en)	2014-05-29
PE20141411A1 (es)	2014-10-29
UA114607C2 (uk)	2017-07-10
AU2012300841C1 (en)	2016-02-18
US9694004B2 (en)	2017-07-04
CR20140098A (es)	2014-05-06
CY1120784T1 (el)	2019-12-11
PT2751094T (pt)	2018-10-19
KR20190075172A (ko)	2019-06-28
LT2751094T (lt)	2018-11-12
CA2847066C (en)	2019-04-30
MY172885A (en)	2019-12-13
HK1198534A1 (en)	2015-05-15
PL2751094T3 (pl)	2018-11-30
AU2016200492B2 (en)	2017-04-20
AU2012300841B2 (en)	2015-10-29
US20160367544A1 (en)	2016-12-22
KR20140056297A (ko)	2014-05-09
EP2751094B1 (en)	2018-06-20
US20140213613A1 (en)	2014-07-31
ES2686563T3 (es)	2018-10-18
US20160075685A1 (en)	2016-03-17

Publication	Publication Date	Title
HK1222753A1 (zh)	2017-07-07	顯示器
GB2492789B (en)	2018-01-03	Displays
EP2702468A4 (en)	2015-02-25	ELECTRO-VIBRO-TACTILE DISPLAY
HK1192332A1 (en)	2014-08-15	Timepiece
AU337152S (en)	2011-06-15	Watch
EP2771126A4 (en)	2015-07-01	FURNACE
AU337151S (en)	2011-06-15	Watch
HK1179359A1 (en)	2013-09-27	Wristwatch
HK1200314A1 (en)	2015-08-07	R()-n-methyl-propargyl-aminoindan r()-n---
PL2771471T3 (pl)	2017-10-31	Konstrukt
HK1200315A1 (en)	2015-08-07	R()-n-formyl-propargyl-aminoindan r()-n---
EP2663331A4 (en)	2015-07-15	NEW USES
HK1201340A1 (en)	2015-08-28	Timepiece
GB201119167D0 (en)	2011-12-21	Novel bachteriophages
GB201301300D0 (en)	2013-03-06	No details
GB201107301D0 (en)	2011-06-15	Alignment
HRP20181375T1 (hr)	2018-10-19	Novi kristalni oblici
GB201109024D0 (en)	2011-07-13	Can
GB201107854D0 (en)	2011-06-22	Novel 5-hydroxy-5-aryl-pyrrol-2-ones
GB201115869D0 (en)	2011-10-26	Display
GB201113206D0 (en)	2011-09-14	Novel uses
GB201108947D0 (en)	2011-07-13	Novel use
GB201103770D0 (en)	2011-04-20	Novel use
GB201103906D0 (en)	2011-04-20	Novel methodology
GB201303586D0 (en)	2013-04-10	No details